Clinical Characteristics, Treatment Effectiveness, and Predictors of Response to Pharmacotherapeutic Interventions in Burning Mouth Syndrome: A Retrospective Analysis

Aims: To identify the clinical characteristics of patients with primary and secondary burning mouth syndrome (BMS), to assess the effectiveness of pharmacotherapy in treating BMS, and to determine the clinical variables that may predict significant relief of clinical symptoms. Methods: A retrospective chart review of patients who underwent clinical management for BMS in the Massachusetts General Hospital between January 2011 and December 2016 was carried out. Information regarding demographics, diagnostics, and therapeutic characteristics was extracted and analyzed. Results: Of 112 BMS patients, 77 had primary BMS. Patients with primary and secondary BMS had similar clinical characteristics except when it came to the presence of at least one symptom of sensory discrepancy, which was more prevalent in primary BMS. Following pharmacologic intervention, 46.8% of the patients with primary BMS experienced significant relief in symptoms, and this therapy was associated with a lower level of pain, an onset of symptoms of less than 1 year, hyperlipidemia, absence of depression disorder, and nonconcurrent use of other neuropathic medications. In contrast, only 31.4% of patients with secondary BMS experienced significant relief in symptoms, and this was associated with the presence of anxiety disorder. Stepwise forward conditional logistic regression analysis suggested that nonconcurrent use of neuropathic medications was a predictor for significant relief of symptoms in patients with primary BMS. Likewise, the model suggested that presence of anxiety disorder was a predictor in patients with secondary BMS. Conclusion: The prevalence of an associated sensory discrepancy was higher in primary BMS. Pharmacologic intervention provided significant relief for approximately half of the patients with primary BMS and nearly one-third of the patients with secondary BMS. Concurrent use of neuropathic medications was a negative predictor, and presence of anxiety disorder a positive predictor, of therapeutic response among patients with primary BMS and secondary BMS, respectively.

burning mouth syndrome; facial pain; neuropathic pain; pain

1. International Headache Society abstracts. Cephalalgia 2015; 35(6 suppl):s1–s296.

2. Klasser GD, Fischer DJ, Epstein JB. Burning mouth syndrome: Recognition, understanding, and management. Oral Maxillofac Surg Clin North Am 2008;20:255–271.

3. Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning mouth syndrome: An update. J Am Dent Assoc 1995;126:842–853.

4. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993;124:115–121.

5. Basker RM, Sturdee DW, Davenport JC. Patients with burning mouths. A clinical investigation of causative factors, including the climacteric and diabetes. Br Dent J 1978;145:9–16.

6. Gorsky M, Silverman S J, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol 1991;72:192–195.

7. Crow HC, Gonzalez Y. Burning mouth syndrome. Oral Maxillofac Surg Clin North Am 2013;25:67–76.

8. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988;296:1243–1246.

9. Spanemberg JC, López López J, de Figueiredo MA, Cherubini K, Salum FG. Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: A randomized, controlled trial. J Biomed Opt 2015;20:098001.

10. Eliav E, Kamran B, Schaham R, Czerninski R, Gracely RH, Benoliel R. Evidence of chorda tympani dysfunction in patients with burning mouth syndrome. J Am Dent Assoc 2007;138:628–633.

11. Nasri-Heir C, Gomes J, Heir GM, et al. The role of sensory input of the chorda tympani nerve and the number of fungiform papillae in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:65–72.

12. Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002;99:41–47.

13. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003;101:149–154.

14. Hagelberg N, Martikainen IK, Mansikka H, et al. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 2002;99:273–279.

15. Albuquerque RJ, de Leeuw R, Carlson CR, Okeson JP, Miller CS, Andersen AH. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: An fMRI study. Pain 2006;122:223–234.

16. Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral PatholOral Radiol Endod 1998;86:557–561.

17. Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope 2012;122:813–816.

18. López-D’alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of burning mouth syndrome: A randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16:e635–e640.

19. Amos K, Yeoh SC, Farah CS. Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: A retrospective pilot study. J Orofac Pain 2011;25:125–130.

20. Macdonald RL, McLean MJ. Anticonvulsant drugs: Mechanisms of action. Adv Neurol 1986;44:713–736.

21. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain 2004;108:51–57.

22. Rose MA, Kam PC. Gabapentin: Pharmacology and its use in pain management. Anaesthesia 2002;57:451–462.

23. Femiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): Controlled open trial of the efficacy of alphalipoic acid (thioctic acid) on symptomatology. Oral Dis 2000;6:274–277.

24. Kassem HS, Azar ST, Zantout MS, Sawaya RA. Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients. Neuro Endocrinol Lett 2005;26:775–779.

25. Wu S, Cao X, He R, Xiong K. Detrimental impact of hyperlipidemia on the peripheral nervous system: A novel target of medical epidemiological and fundamental research study. Neural Regen Res 2012;7:392–399.

26. Miller LG, Greenblatt DJ, Barnhill JG, Shader RI. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function. J Pharmacol Exp Ther 1988;246:170–176.

27. Gent JP, Feely MP, Haigh JR. Differences between the tolerance characteristics of two anticonvulsant benzodiazepines. LifeSci 1985;37:849–856.

28. Schweizer E, Rickels K, Lucki I. Resistance to the antianxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 1986;314:719–720.

29. Behrbalk E, Halpern P, Boszczyk BM, et al. Anxiolytic medication as an adjunct to morphine analgesia for acute low back pain management in the emergency department: A prospective randomized trial. Spine (Phila Pa 1976) 2014;39:17–22.

30. Zoric B, Jankovic L, Kuzmanovic Pficer J, Zidve-Trajkovic J, Mijajlovic M, Stanimirovic D. The efficacy of fluoxetine in BMS—A cross-over study. Gerodontology 2018;35:123–128.